Ernexa Therapeutics Inc.: Form 10-Q for the period ended Sep 30, 2017
Filed with the SEC on Nov 8, 2017 and accepted by EDGAR at Nov 8, 2017, 16:31 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Selling, general and administrative | 3 months2017-07-01 to 2017-09-30 | $3.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2017-01-01 to 2017-09-30 | $11.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2017-07-01 to 2017-09-30 | −$53.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2017-01-01 to 2017-09-30 | −$913.0k | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2017-07-01 to 2017-09-30 | $9.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2017-01-01 to 2017-09-30 | $21.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-07-01 to 2017-09-30 | −$184.0k | us-gaap:NetIncomeLoss |
| Net income | 9 months2017-01-01 to 2017-09-30 | −$438.0k | us-gaap:NetIncomeLoss |
| Operating cash flow | 9 months2017-01-01 to 2017-09-30 | $1.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2017-01-01 to 2017-09-30 | $562.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2017-09-30 | $4.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-09-30 | $10.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-09-30 | $17.6m | us-gaap:Assets |
| Current liabilities | At period end2017-09-30 | $10.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-09-30 | $11.5m | us-gaap:Liabilities |
| Current portion of debt | At period end2017-09-30 | $5.2m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2017-09-30 | $6.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-17-012607. Last ingested by Listed: Nov 6, 2026, 17:52 ET. Listed shows no prices and gives no investment advice.